Nurix Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Good afternoon, everyone, and thank you for joining me at the fourth day of the Needham & Company Healthcare Conference. My name is Gil Blum, and I am a senior biotech analyst here at Needham and I cover the immuno-oncology and gene therapy subsectors. It is my pleasure to have with me today Nurix's CEO, Dr. Arthur Sands.
As a reminder, any viewers who are watching through our conference portal are able to submit questions via the Ask a Question box below the video feed window.
Questions & Answers
So Arthur, maybe a good place to start just as an overview, provide some introductory remarks on Nurix. And not everyone is familiar with protein degradation, but what is it and how is Nurix doing it different?
Certainly. And first off, thanks, Gil, and thanks to the Needham team for hosting us. So targeted protein degradation, I can dive in and say one of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |